Jasper Therapeutics (JSPR) Consolidated Net Income (2020 - 2025)

Jasper Therapeutics' Consolidated Net Income history runs 6 years deep, the most recent figure standing at -$16.0 million for Q4 2025.

• In Q4 2025, Consolidated Net Income rose 35.08% year-over-year to -$16.0 million; the TTM figure through Dec 2025 stood at -$85.1 million (down 11.17% YoY), while the FY2025 annual figure was -$84.0 million, down 7.94% from the prior year.
• Consolidated Net Income for Q4 2025 stood at -$16.0 million, up from -$18.9 million in the prior quarter.
• The five-year high for Consolidated Net Income was $5.5 million in Q1 2021, with the low at -$28.9 million in Q2 2025.
• The 5-year median for Consolidated Net Income is -$15.5 million (2024), against an average of -$15.4 million.
• Peak annual rise in Consolidated Net Income reached 284.79% in 2021, while the deepest fall reached 4536.03% in 2021.
• Jasper Therapeutics' Consolidated Net Income stood at -$11.9 million in 2021, then decreased by 19.41% to -$14.2 million in 2022, then slipped by 17.77% to -$16.8 million in 2023, then slumped by 46.88% to -$24.6 million in 2024, then surged by 35.08% to -$16.0 million in 2025.
• Business Quant data shows JSPR's Consolidated Net Income at -$16.0 million in Q4 2025, -$18.9 million in Q3 2025, and -$28.9 million in Q2 2025.